Effects of Bifidobacterium Longum BB536 on Incidence of Acute Diarrhea and/or Respiratory- Related Illnesses in Children
Study on Oral Administration of Bifidobacterium Longum BB536 on Incidence of Acute Diarrhea and/or Respiratory- Related Illnesses Compared to Placebo
1 other identifier
interventional
520
1 country
1
Brief Summary
This project aims to study the benefits of probiotics namely Bifidobacterium longum BB536 in prevention of acute diarrhea and/or respiratory-related illnesses, which are found common among children in Malaysia aged from 2 to 6 years.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for not_applicable healthy-volunteers
Started Apr 2015
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
April 1, 2015
CompletedFirst Submitted
Initial submission to the registry
April 29, 2015
CompletedFirst Posted
Study publicly available on registry
May 5, 2015
CompletedPrimary Completion
Last participant's last visit for primary outcome
February 28, 2016
CompletedStudy Completion
Last participant's last visit for all outcomes
February 28, 2016
CompletedNovember 6, 2017
November 1, 2017
11 months
April 29, 2015
November 2, 2017
Conditions
Keywords
Outcome Measures
Primary Outcomes (3)
Absentia between BB536 vs. Placebo children in daycare centers due to diarrhea and/or respiratory-related illnesses
10 monhts
Severity of diarrhea between BB536 vs. Placebo children
10 months
Severity of respiratory-related illnesses between BB536 vs. Placebo children
10 months
Secondary Outcomes (1)
Fecal microbiota profiles of BB536 vs. Placebo children
10 months
Study Arms (2)
BB536
ACTIVE COMPARATORBifidobacterium longum BB536 (9 log CFU/day) and dextrin
Placebo
PLACEBO COMPARATOR100% dextrin
Interventions
Intervention consists of daily administration of 1g probiotic Bifidobacterium longum BB536, administer daily for five days a week at a fixed dosage of 9 log CFU/day for BB536 and continue for 10 months.
Intervention consists of daily administration of 1g of 100% dextrin, administer daily for five days a week and continue for 10 months.
Eligibility Criteria
You may qualify if:
- Healthy male/ female subjects
- years old
- BMI within a healthy range (between 5th to 84th percentile according to children BMI-for-age chart)
- Willing to commit throughout the experiment
You may not qualify if:
- Type-1 diabetes
- Long term medication due to certain severe illness
- HIV/AIDS
- Glucose-6-phosphate dehydrogenase (G6PD) deficiency
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Universiti Sains Malaysialead
- Morinaga Milk Industry Co., LTDcollaborator
Study Sites (1)
School of Industrial Technology, Universiti Sains Malaysia
Pulau Pinang, 11900, Malaysia
MeSH Terms
Interventions
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Min Tze Liong, PhD
Universiti Sains Malaysia
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- TRIPLE
- Who Masked
- PARTICIPANT, CARE PROVIDER, INVESTIGATOR
- Purpose
- PREVENTION
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Associate Professor Dr
Study Record Dates
First Submitted
April 29, 2015
First Posted
May 5, 2015
Study Start
April 1, 2015
Primary Completion
February 28, 2016
Study Completion
February 28, 2016
Last Updated
November 6, 2017
Record last verified: 2017-11